Tag: AKBA

Blue Horseshoe Stocks: Options, Bottom-Plays & More

Twitter, Inc. TWTR – Options Idea

We have yet to talk about TWTR in 2017, namely because the stock has been in an overall downtrend over nearly that whole span. However, in recent weeks, it found a bottom and slowly has begun stair-stepping its way to a recovery. That process is getting a kick in the pants this morning with a significant morning gap up on the heels of Twitter’s earnings. The company posted losses, though not as big as expected, while also reporting an increase in users.

We’re going to see about possibly using the commotion to our advantage with a range of options ideas. Provided TWTR can maintain support at or above its 50DMA (15.19) on any pullbacks, we’re going to be interested in tracking the activity in the TWTR Weekly $15-16 Calls, on which we’ll be looking for a classic dip-and-rip pattern. If properly timed, it could spell some big gains in those contracts.

Apricus Biosciences, Inc. APRI

We want to put APRI on our radars today as a potential bottom-bouncer. At the beginning of the year, from a level comparable to current prices, the stock ran into the mid-$3 range. Now, after a long period of getting beat back nearly to its annual low, it is showing signs of a rebound that we’d like to monitor on the chance that it turns into a full-scale reversal.

You can see just what we mean on the snapshot below. The RSI is indicating that APRI is about to enter extreme oversold territory, while the MACD is just beginning to curl upward and show some convergence. We wouldn’t be surprised to a see cross in the days ahead.

Even just a run back to the 200DMA from here would be a move of almost 100% so we’ll definitely want to keep an eye peeled.

.

NoHo, Inc. DRNK

We’ve been saying how hot the super-subpenny market has been recently, and the trend has been persisting now for quite some time.  We initially slated DRNK for observation in Monday’s premarket report, after which we saw a soild 70% pop from a low of .0003. We stated as much in yesterday’s report, mentioning that we’d certainly want to continue to pay attention, based on a number of factors.

The stock did manage to record a new high for us for the second straight day, making an intraday move of 50% from .0004-.0006, and extending our two-session observed range to a nice, round 100%

Extended Watchlist:
AAGC, KALY, AKBA, CETV, SDLP, UQM

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: Bottom-Plays, Options & More

Novavax, Inc. NVAX

Our first item of interest this morning is going to be NVAX. This play set off our alarms on Friday when the stock was downgraded on the heels of ill-received trial data on the company’s RSV (respiratory syncytial virus) vaccine.

Whenever we see knee-jerk reactions take place, and Friday’s backslide of more than 80% certainly qualifies in that category, we like to place the battered stocks on watch for the subsequent recoveries that occur as often as not.

With the monster gap that Friday’s activity left on the chart (1.20’s to 8.10’s), it will be very interesting to see how the stock responds as we kick off a fresh trading week. Prior to that it had been on a fairly steady four month uptrend that almost reached the 100%-mark. All these factors playing in at once are plenty enough to reserve a slot for NVAX on our radars in coming sessions.

Netflix, Inc. NFLX – Options Idea

We’ve tracked NFLX options to great success on multiple occasion in the past, and today seems like a good time to take another run at it. Along with being on the uptrend for the past six or seven weeks, the stock breached its 200DMA in a bullish manner on Friday, a signal that further advances could be in the cards this week. NFLX is gapping up slightly in the premarket this morning.

In accordance, we want to have an options idea ready and waiting to take advantage should a continued surge be in the cards. The targets we want to zero in on are the NFLX Weekly $99.50-101 Calls for potential swing trades.


APT Systems, Inc. APTY

We alerted our readers to a PR put out by APTY on Friday alluding to the planned purchase of shares out of the open market by the company’s CEO. That coincided with a reasonable amount of momentum that the stock had carried into that session from the one prior.

We mentioned that we liked the chances of the stock seeing some further increases for Friday’s session, and we weren’t disappointed on that front. APTY traded in a solid range from .0032 to .0044, a respectable intraday gain totaling 38%

We’ll remain interested in this play provided it can maintain support above Friday’s swing-low of .0032.

Extended Watchlist:
USLV, CFRX, NWBO, AKBA, ETRM, PTIE